[go: up one dir, main page]

WO2009007679A3 - Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist - Google Patents

Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist Download PDF

Info

Publication number
WO2009007679A3
WO2009007679A3 PCT/GB2008/002247 GB2008002247W WO2009007679A3 WO 2009007679 A3 WO2009007679 A3 WO 2009007679A3 GB 2008002247 W GB2008002247 W GB 2008002247W WO 2009007679 A3 WO2009007679 A3 WO 2009007679A3
Authority
WO
WIPO (PCT)
Prior art keywords
thromboxane
atherosclerosis
antagonist
mast cell
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/002247
Other languages
French (fr)
Other versions
WO2009007679A2 (en
Inventor
Johan Raud
Carl-Johan Dalsgaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardoz AB
Original Assignee
Cardoz AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardoz AB filed Critical Cardoz AB
Publication of WO2009007679A2 publication Critical patent/WO2009007679A2/en
Publication of WO2009007679A3 publication Critical patent/WO2009007679A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There is provided combination products comprising (a) a mast cell inhibitor, or a pharmaceutically-acceptable salt or solvate thereof; and (b) a thromboxane A2 antagonist, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in atherosclerosis and related conditions.
PCT/GB2008/002247 2007-07-11 2008-06-25 Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist Ceased WO2009007679A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92973007P 2007-07-11 2007-07-11
US92972507P 2007-07-11 2007-07-11
US60/929,725 2007-07-11
US60/929,730 2007-07-11

Publications (2)

Publication Number Publication Date
WO2009007679A2 WO2009007679A2 (en) 2009-01-15
WO2009007679A3 true WO2009007679A3 (en) 2009-03-12

Family

ID=39769161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/002247 Ceased WO2009007679A2 (en) 2007-07-11 2008-06-25 Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist

Country Status (1)

Country Link
WO (1) WO2009007679A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120329813A1 (en) * 2009-11-13 2012-12-27 Cardoz Ab Pemirolast for the Treatment of Systemic Low Grade Inflammation
CN103450087B (en) * 2013-09-13 2015-07-01 上海海虹实业(集团)巢湖今辰药业有限公司 Preparation method of paeonol and ozagrel conjugate
MY184873A (en) * 2015-03-23 2021-04-28 Teika Pharmaceutical Co Ltd Therapeutic agent for sjogren's syndrome dry eye
JP7399949B2 (en) * 2018-07-06 2023-12-18 アルジャーノン・ファーマスーティカルズ・インコーポレイテッド Compositions and methods for the treatment of non-alcoholic steatohepatitis
CN110637788B (en) * 2019-11-05 2022-01-14 云南洛宇生物科技有限公司 Method for establishing rabbit atherosclerosis animal model

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086349A (en) * 1975-07-30 1978-04-25 Mitsubishi Yuka Pharmaceutical Co., Ltd. Quinolopyran-4-one-2-carboxylic acid derivatives and salts thereof as novel compounds and as medicines for treatment of allergic asthma
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
EP0316174A1 (en) * 1987-11-10 1989-05-17 Tokyo Tanabe Company Limited Aqueous preparation of 9-methyl-3-(1H-tetrazol-5-yl)-4H-Pyrido[1,2-a]pyrimidin-4-one potassium salt
EP0766963A1 (en) * 1994-05-31 1997-04-09 Tokyo Tanabe Company Limited Arteriosclerosis depressant
US20020103219A1 (en) * 2000-10-05 2002-08-01 Jeremy Jacob Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders
EP1285921A1 (en) * 2001-08-10 2003-02-26 Dinamite Dipharma S.p.A. A process for the preparation of high purity pemirolast
US6585995B1 (en) * 1999-09-21 2003-07-01 Hanson Stephen R Methods and compositions for treating platelet-related disorders

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086349A (en) * 1975-07-30 1978-04-25 Mitsubishi Yuka Pharmaceutical Co., Ltd. Quinolopyran-4-one-2-carboxylic acid derivatives and salts thereof as novel compounds and as medicines for treatment of allergic asthma
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
EP0316174A1 (en) * 1987-11-10 1989-05-17 Tokyo Tanabe Company Limited Aqueous preparation of 9-methyl-3-(1H-tetrazol-5-yl)-4H-Pyrido[1,2-a]pyrimidin-4-one potassium salt
EP0766963A1 (en) * 1994-05-31 1997-04-09 Tokyo Tanabe Company Limited Arteriosclerosis depressant
US6585995B1 (en) * 1999-09-21 2003-07-01 Hanson Stephen R Methods and compositions for treating platelet-related disorders
US20020103219A1 (en) * 2000-10-05 2002-08-01 Jeremy Jacob Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders
EP1285921A1 (en) * 2001-08-10 2003-02-26 Dinamite Dipharma S.p.A. A process for the preparation of high purity pemirolast

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
"PEMIROLAST POTASSIUM", DRUGS OF TODAY / MEDICAMENTOS DE ACTUALIDAD, J.R. PROUS SS.A. INTERNATIONAL PUBLISHERS, ES, vol. 28, no. 1, 1 January 1992 (1992-01-01), pages 29 - 31, XP008066535, ISSN: 0025-7656 *
AKAGI MASAAKI ET AL: "Inhibitory effect of egualen sodium: A new stable derivative of azulene on histamine release from mast cell-like cells in the stomach", PHARMACOLOGY (BASEL), vol. 63, no. 4, November 2001 (2001-11-01), pages 203 - 209, XP008086936, ISSN: 0031-7012 *
COLLINS C E ET AL: "Anti-platelet therapy in active Crohn's disease: An open trial using picotamide, a thromboxane antagonist", GASTROENTEROLOGY, vol. 108, no. 4 SUPPL., 1995, & 95TH ANNUAL MEETING OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION AND DIGESTIVE DISEASE WEEK; SAN DIEGO, CALIFORNIA, USA; MAY 14-17, 1995, pages A799, XP008086946, ISSN: 0016-5085 *
COLLINS C E ET AL: "PICOTAMIDE INHIBITION OF EXCESS IN VITRO THROMBOXANE B2 RELEASE BY COLORECTAL MUCOSA IN INFLAMMATORY BOWEL DISEASE", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, BLACKWELL SCIENTIFIC PUBLICATIONS LTD., CAMBRIDGE, GB, vol. 10, no. 3, 1996, pages 315 - 320, XP009040236, ISSN: 0269-2813 *
DOGNE J-M ET AL: "Recent developments of thromboxane modulators", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 11, no. 11, 2001, pages 1663 - 1675, XP002445841, ISSN: 1354-3776 *
ISAJI M ET AL: "TRANILAST INHIBITS THE PROLIFERATION, CHEMOTAXIS AND TUBE FORMATIONOF HUMAN MICROVASCULAR ENDOTHELIAL CELLS IN VITRO AND ANGIOGENESIS IN VIVO", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 122, no. 6, November 1997 (1997-11-01), pages 1061 - 1066, XP000997892, ISSN: 0007-1188 *
ISHIZUKA T: "THROMBOXANE A2 RECEPTOR BLOCKADE PREVENTS ATHEROSCLEROTIC PROCESS BY ITS ANTI-INFLAMMATORY EFFECT", VASCULAR DISEASE PREVENTION, BENTHAM SCIENCE PUBLISHERS, GB, vol. 3, no. 2, May 2006 (2006-05-01), pages 143 - 148, XP008078040, ISSN: 1567-2700 *
JONES N L ET AL: "Ketotifen therapy for acute ulcerative colitis in children: A pilot study", DIGESTIVE DISEASES AND SCIENCES, PLENUM PUBLISHING CO, US, vol. 43, no. 3, 1 March 1998 (1998-03-01), pages 609 - 615, XP008086243, ISSN: 0163-2116 *
MARSHALL J K ET AL: "Ketotifen treatment of active colitis in patients with 5-aminosalicylate intolerance", CANADIAN JOURNAL OF GASTROENTEROLOGY, MEDICARE PUBL., OAKVILLE, CA, vol. 12, no. 4, 1998, pages 273 - 275, XP008086245, ISSN: 0835-7900 *
MATSUMURA ET AL: "Suppression of atherosclerotic development in watanabe heritable hyperlipidemic rabbits treated with an oral antiallergic drug, tranilast", MEDLINE, 23 February 1999 (1999-02-23), XP002953929 *
MINOCHA A ET AL: "Role of ketotifen in pathogenesis of chronic ulcerative colitis", GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA,, US, vol. 104, no. 4 SUPPL, 1993, pages A746, XP008086242, ISSN: 0016-5085 *
MYOU SHIGEHARU ET AL: "Effect of ozagrel hydrochloride, a thromboxane synthetase inhibitor, on alcoholic beverage-induced bronchoconstriction in asthmatic patients", PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, vol. 66, no. 4, April 2002 (2002-04-01), pages 397 - 401, XP008086945, ISSN: 0952-3278 *
NOBUHIDE O ET AL: "Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn's disease", GUT, BRITISH MEDICAL ASSOCIATION, LONDON,, GB, vol. 56, no. 4, April 2007 (2007-04-01), pages 599 - 600, XP008086231, ISSN: 0017-5749 *
SAIURA A ET AL: "Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 433, no. 2-3, 21 December 2001 (2001-12-21), pages 163 - 168, XP008086230, ISSN: 0014-2999 *
SHIMIZU T ET AL: "INHIBITORY EFFECTS OF AZELASTINE AND TRANILAST ON LEUKOTRIENE B4 AND LEUKOTRIENE C4, GENERATION BY RAT COLONIC MUCOSA", PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, CHURCHILL LIVINGSTONE MEDICAL JOURNALS,, GB, vol. 53, no. 5, 1995, pages 355 - 358, XP001042184, ISSN: 0952-3278 *
SORBERA L A ET AL: "Terutroban sodium. Prostanoid TP receptor antagonist, antithrombotic agent, antiatherosclerotic agent", DRUGS OF THE FUTURE, BARCELONA, ES, vol. 31, no. 10, October 2006 (2006-10-01), pages 867 - 873, XP008086411, ISSN: 0377-8282 *
SUWAKI T ET AL: "Modification of eosinophil function by suplatast tosilate (IPD), a novel anti-allergic drug", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 1, no. 12, November 2001 (2001-11-01), pages 2163 - 2171, XP002443957, ISSN: 1567-5769 *
TAKAHASHI N ET AL: "Beneficial effect of combination therapy with ozagrel and pranlukast in exercise-induced asthma demonstrated by krypton-81m ventilation scintigraphy: A case report", ANNALS ACADEMY OF MEDICINE SINGAPORE, vol. 29, no. 6, November 2000 (2000-11-01), pages 766 - 769, XP008086937, ISSN: 0304-4602 *
TAMAOKI JUN: "Role of a Th2 cytokine inhibitor in asthma treatment", ALLERGOLOGY INTERNATIONAL, BLACKWELL SCIENCE, CARLTON,, AU, vol. 53, no. 2, June 2004 (2004-06-01), pages 55 - 60, XP002443956, ISSN: 1323-8930 *
TEH L G ET AL: "Does the addition of ketotifen to non-steroidal anti-inflammatory drugs confer any additional benefit in rheumatoid arthritis?", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, BLACKWELL SCIENTIFIC PUBL, GB, vol. 17, no. 2, 1984, pages 157 - 159, XP008086082, ISSN: 0306-5251 *
YAMADA N ET AL: "MY-1250, a major metabolite of the anti-allergic drug repirinast, induces phosphorylation of a 78-kDa protein in rat mast cells", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 44, no. 6, 25 September 1992 (1992-09-25), pages 1211 - 1213, XP023732179, ISSN: 0006-2952, [retrieved on 19920925] *
YANAGIHARA Y ET AL: "Immunopharmacological studies on TBX, a new antiallergic drug. (4) Effects on type II to IV allergic reactions and immunological functions in animal models", JAPANESE JOURNAL OF PHARMACOLOGY, JPTHE JAPANESE PHARMACOLOGICAL SOCIETY, KYOTO, vol. 51, no. 1, 1 January 1989 (1989-01-01), pages 93 - 100, XP008066536, ISSN: 0021-5198 *
ZHANG W ET AL: "Development of new therapeutic effect and mechanism of tranilast", ZHONGGUO XIN YAO YU LINCHUANG ZAZHI - CHINESE JOURNAL OF NEW DRUGS AND CLINICAL REMEDIES, SHANGHAI SHI YIYAO GUANLIJU KE-JI QINGBAO YANJIUSUO ZHONGGUO, CN, vol. 23, no. 11, November 2004 (2004-11-01), pages 795 - 798, XP008086232, ISSN: 1007-7669 *

Also Published As

Publication number Publication date
WO2009007679A2 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
WO2009007673A3 (en) Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a ppar gamma agonist
WO2009007675A3 (en) Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist
EP2607348B8 (en) Plasminogen Activator Inhibitor-1 Inhibitor
IL192603A0 (en) Thieno-pyridine derivatives as mek inhibitors
IT1393867B1 (en) WORK STATION FOR COMPUTERS AND THE LIKE, PARTICULARLY FOR EDUCATIONAL USE
EP2123314A4 (en) Continuously working and portable haemodialysis apparatus
IL197708A0 (en) Process for the fabrication of manometric, zonodispersed and stable magnesium hydroxide and product obtained
WO2009007679A3 (en) Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist
AU2007337830A8 (en) Benzenesulfonamide derivatives as HIV protease inhibitors
WO2009007674A3 (en) Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and ramatroban or seratrodast
MX2009006507A (en) New combination for use in the treatment of inflammatory disorders.
SI2125736T1 (en) Substituted acetophenones useful as pde4 inhibitors
WO2009007680A3 (en) Combinations comprising a mast cell inhibitor and a statin for use in the treatment of inflammatory disorders
IL201168A0 (en) New combination for use in the treatment of inflammatory disorders
GB2436697B (en) Utility knife
WO2007035964A3 (en) Vigabatrin bioisoteres and related methods of use
张艳 Water-saving
AU2006905290A0 (en) Fast minkowski hull operations
HK1139146A (en) Heterocyclic compounds and use thereof as erk inhibitors
AU2006906611A0 (en) Portable computer
AU2008229924A1 (en) "Slop and tap" bricklayer companion tool
AU2009905721A0 (en) Portable Desktop Computer
AU2006904990A0 (en) Work Stand
AU2006903310A0 (en) Notebook computer stand
HK1136281A (en) Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08762519

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08762519

Country of ref document: EP

Kind code of ref document: A2